試す 金 - 無料
Rounding up Digital Health Advancements across APAC in 2022
BioSpectrum Asia
|December 2022
Over the past two years, Digital Health has been propelled into a realm of new care to create better efficiency, patient experience, while improving patient outcomes.
-

Globally, priorities in healthcare are shifting towards modernised patient care by streamlining processes and task automation. Telehealth and telemedicine as we know it is becoming a common inclusion for both healthcare providers and insurance programmes with increased attention to the quality and outcomes of virtual care and the data driven clinical decision-making. As per Health Tech Alpha in 2022, more than 130 partnerships were closed globally between telemedicine Digital Health ventures and corporations, doubling the number of disclosed telemedicine partnerships in 2021. Being home to more than 3,300 Digital Health ventures, Asia Pacific (APAC) represented historically the second largest Digital Health ecosystem globally, with the two world’s most populous countries, namely China and India, accountable for approximately 50 per cent of those ventures. Against the backdrop of growing inequities in access to quality and affordable healthcare, especially for marginalised populations, the growing cost pressure on healthcare systems and global advancements in technologies, Digital Health businesses remain bullish to adapt to address health challenges on a local scale. While China has stuck to its ‘zero-COVID’ policy, advancements of Digital Health technologies in 2022 were more apparent in North-East Asia, South-East Asia, and South Asia as measured by partnerships, regulatory approvals and the amount of funding invested.
このストーリーは、BioSpectrum Asia の December 2022 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、9,500 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Translate
Change font size